Brief: Replimune Announces Favorable Outcome Of FDA's Cellular, Tissue, And Gene Therapies Advisory Committee Meeting For Rp1 In Advanced Melanoma
30/07/2026 23:33
BRIEF-Replimune Announces Favorable Outcome Of FDA's Cellular, Tissue, And Gene Therapies Advisory Committee Meeting For Rp1 In Advanced Melanoma July 30 (Reuters) - Replimune Group Inc REPL.O:
REPLIMUNE ANNOUNCES FAVORABLE OUTCOME OF FDA'S CELLULAR, TISSUE, AND GENE THERAPIES ADVISORY COMMITTEE MEETING FOR RP1 IN ADVANCED MELANOMA
REPLIMUNE GROUP - FDA TARGET ACTION DATE FOR RP1 BLA RESUBMISSION IS AUGUST 2, 2026
Source text: ID:nGNX8QMmcw
Further company coverage: REPL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Replimune
See all newsTrump picks White House adviser Heidi Overton to run FDA, source says (updated)
Brief: Replimune Group, Inc. Files For Mixed Shelf Size Not Disclosed
Brief: Replimune Reports Fiscal First Quarter 2027 Financial Results And Provides Corporate Update
Replimune Q1 net loss narrows as expenses decline
U.S. STOCKS ON THE MOVE-Microsoft, Coastal Financial, Eli Lilly